Skip to main content
Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze TGTX TG Therapeutics, Inc.: https://finlab.finance/en/setup?stock=TGTX”

Run AI in browser

TGTX

TG Therapeutics, Inc. Healthcare As of 2026-06-18
Quality Above avg
Valuation Expensive
Risk Moderate
Active signals Active 52-week adjusted-price high Top-quintile 6-month momentum
53.22 Close (USD)
+76.11% 60-day
  • Quality is above average. Operating margin sits near the 75th percentile. TTM ROE is about 79.2%.
  • Valuation is expensive. TTM P/E is in the 72th percentile, above most peers.
  • Recent volatility is moderate. 60-day annualized volatility is near the 70th percentile. Average 20-day dollar volume is about $109.1M.
  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Factor profile

Factor radar Weak Valuation
26
ValuationQualityGrowthMomentumRisk / liquidity

Valuation

Indicators in this group are ranked by market percentile; lower valuation and volatility are better.

26 Weak
TTM P/E 18.61
Pricey
Price / book 13.18
Expensive
Free-cash-flow yield (%) -0.18
Average

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

18 historical occurrences (since 2017-03-07)
Average forward return after 52-week adjusted-price high。20-day: Win 52.9%, Sample 17, Median +1.38%, Excess +5.4%, Beat mkt rate 47.1%；60-day: Win 81.2%, Sample 16, Median +19.07%, Excess +14.65%, Beat mkt rate 75%；120-day: Win 68.8%, Sample 16, Median +32.64%, Excess +23.01%, Beat mkt rate 68.8%

120 days after: historical avg +32.04%

20-day +6.38%
60-day +19.67%
120-day +32.04%
20-day
60-day
120-day
Win
52.9%
81.2%
68.8%
Sample
17
16
16
Median
+1.38%
+19.07%
+32.64%
Excess
+5.4%
+14.65%
+23.01%
Beat mkt rate
47.1%
75%
68.8%

Over 16 occurrences, 120-day forward avg gained 32.04%, beat the market by 23.01 pts; win rate 68.8%.

Top-quintile 6-month momentum

Active · now 88.05084745762713%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

16 historical occurrences (since 2017-03-06)
Average forward return after Top-quintile 6-month momentum。20-day: Win 66.7%, Sample 15, Median +6.03%, Excess +6.59%, Beat mkt rate 60%；60-day: Win 60%, Sample 15, Median +3.07%, Excess +13.49%, Beat mkt rate 53.3%；120-day: Win 60%, Sample 15, Median +17.16%, Excess +34.6%, Beat mkt rate 60%

120 days after: historical avg +41.64%

20-day +7.68%
60-day +16.55%
120-day +41.64%
20-day
60-day
120-day
Win
66.7%
60%
60%
Sample
15
15
15
Median
+6.03%
+3.07%
+17.16%
Excess
+6.59%
+13.49%
+34.6%
Beat mkt rate
60%
53.3%
60%

Over 15 occurrences, 120-day forward avg gained 41.64%, beat the market by 34.6 pts; win rate 60%.

Market-wide momentum baseline

Across 94,737 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.40%, a 58.3% positive-return rate, and +3.10 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

9 times historically; 60-day forward avg -11.46%, win rate 33.3%, beating the market by -12.66 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

14 times historically; 60-day forward avg +8.44%, win rate 38.5%, beating the market by +4.97 pts on average.

Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze TGTX TG Therapeutics, Inc.: https://finlab.finance/en/setup?stock=TGTX”

Run AI in browser

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.